Primary Site >> Colorectal Cancer
Gene >> UGT1A1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Glucuronidation of 2-hydroxyamino-1-methyl-6-phenylimidazo[4, 5-b]pyridine by human microsomal UDP-glucuronosyltransferases: identification of specific UGT1A family isoforms involved. PMID: 10357796 Ref: Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. PMID: 10606239 |
Ref: Identification of uridine diphosphate glucuronosyltransferases involved in the metabolism and clearance of mycophenolic acid. PMID: 10688250 Ref: Bilirubin UDP-glucuronosyltransferase 1A1 gene polymorphisms: susceptibility to oxidative damage and cancer? PMID: 11170257 |
Ref: Determinants of prognosis and response to therapy in colorectal cancer. PMID: 11177741 |
Ref: UGT1A1 polymorphisms and colorectal cancer susceptibility. PMID: 12010871 |
Ref: Glucuronides of tea catechins: enzymology of biosynthesis and biological activities. PMID: 12642472 |
Ref: Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. PMID: 15297419 Ref: Genetic polymorphisms in UDP-glucuronosyltransferases and glutathione S-transferases and colorectal cancer risk. PMID: 15319294 Ref: Pharmacogenetics of irinotecan toxicity. PMID: 15469406 Ref: Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. PMID: 15523087 |
Ref: UDP-glucuronosyltransferases 1A expression in human urinary bladder and colon cancer by immunohistochemistry. PMID: 15643497 Ref: Unfavourable expression of pharmacologic markers in mucinous colorectal cancer. PMID: 15655543 Ref: Polymorphisms of uridine-diphosphoglucuronosyltransferase 1A7 gene in Taiwan Chinese. PMID: 15682470 Ref: The effects of coffee on conjugation reactions in human colon carcinoma cells. PMID: 15684482 Ref: UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. PMID: 15709193 Ref: Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications. PMID: 15727486 Ref: Link between colorectal cancer and polymorphisms in the uridine-diphosphoglucuronosyltransferase 1A7 and 1A1 genes. PMID: 15929176 Ref: A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors. PMID: 15930350 Ref: [Induction of uridine 5'-diphosphate-glucuronosyltransferase gene expression by sulforaphane and its mechanism: experimental study in human colon cancel cells]. PMID: 15949398 Ref: Molecular genetics of unconjugated hyperbilirubinemia in Taiwanese. PMID: 15965581 Ref: Cancer and molecular biomarkers of phase 2. PMID: 16399374 |
Ref: A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer. PMID: 16003560 Ref: Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. PMID: 16456808 Ref: Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer. PMID: 16551870 Ref: [The role of NF-E2-related factor 2 in the induction of uridine 5'-diphosphate-glucuronosyltransferase 1A and its isoforms by epigallocatechin gallate in colon cancer cells]. PMID: 16620709 Ref: Individualizing chemotherapeutic treatment of colorectal cancer. PMID: 16641252 Ref: Pharmacogenomics: from bedside to clinical practice. PMID: 16651374 Ref: Turmeric and curcumin modulate the conjugation of 1-naphthol in Caco-2 cells. PMID: 16819192 Ref: Glucuronidation of SN-38 and NU/ICRF 505 in human colon cancer and adjacent normal colon. PMID: 16821585 Ref: Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients. PMID: 16865249 Ref: Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan. PMID: 16877259 Ref: Pharmacogenomics of colorectal cancer prevention and treatment. PMID: 16982469 Ref: Irinotecan cytotoxicity does not necessarily depend on the UGT1A1 polymorphism but on fluoropyrimidine: a molecular case report. PMID: 17016579 Ref: Isothiocyanate iberin modulates phase II enzymes, posttranslational modification of histones and inhibits growth of Caco-2 cells by inducing apoptosis. PMID: 17167713 |
Ref: Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxa PMID: 17273745 Ref: Glucuronidation of PhIP and N-OH-PhIP by UDP-glucuronosyltransferase 1A10. PMID: 17638922 Ref: Inhibition of epigallocatechin gallate on orthotopic colon cancer by upregulating the Nrf2-UGT1A signal pathway in nude mice. PMID: 17657175 Ref: [Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients]. PMID: 18478930 |
Ref: Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. PMID: 17549067 Ref: UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. PMID: 18300238 Ref: Targeted therapy of cancer: new roles for pathologists in colorectal cancer. PMID: 18437170 Ref: Cost-effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer. PMID: 18466101 Ref: Family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A): from Gilbert's syndrome to genetic organization and variability. PMID: 18491077 Ref: Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. PMID: 18509181 Ref: Genotyping panel for assessing response to cancer chemotherapy. PMID: 18547414 Ref: UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. PMID: 18594531 Ref: UGT1A1 and UGT1A9 functional variants, meat intake, and colon cancer, among Caucasians and African-Americans. PMID: 18675828 Ref: Pharmacogenetics in colorectal cancer: a systematic review. PMID: 18681783 Ref: Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients. PMID: 18797458 Ref: [Is it possible to individualize prescription of medical treatment in colorectal cancer? The clinician point of view]. PMID: 19004722 Ref: [The biological point of view on pharmacogenetics of anticancer agents in colorectal cancer]. PMID: 19004723 Ref: Pharmacogenomics of tamoxifen and irinotecan therapies. PMID: 19059062 Ref: Utility of Pretreatment Bilirubin Level and UGT1A1 Polymorphisms in Multivariate Predictive Models of Neutropenia Associated with Irinotecan Treatment in Previously Untreated Patients with Colorectal Cancer. PMID: 19639031 |
Ref: C-reactive protein genotypes and haplotypes, polymorphisms in NSAID-metabolizing enzymes, and risk of colorectal polyps. PMID: 19077918 Ref: Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. PMID: 19125129 Ref: Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. PMID: 19364970 Ref: Pharmacogenetics in chemotherapy of colorectal cancer. PMID: 19414151 Ref: UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan. PMID: 19450125 Ref: Pharmacogenetics in pancreatic cancer. Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. PMID: 19581734 Ref: [Two cases of advanced colorectal cancer with UGT1A1*28 homozygosity treated by FOLFIRI]. PMID: 19620808 Ref: Pharmacogenetics of solid tumors: directed therapy in breast, lung, and colorectal cancer: a paper from the 2008 william beaumont hospital symposium on molecular pathology. PMID: 19644023 Ref: Tissue biomarker development in a multicentre trial context: a feasibility study on the PETACC3 stage II and III colon cancer adjuvant treatment trial. PMID: 19690194 Ref: Modulation of NRF2 and UGT1A expression by epigallocatechin-3-gallate in colon cancer cells and BALB/c mice. PMID: 19719968 Ref: Networking of differentially expressed genes in human cancer cells resistant to methotrexate. PMID: 19732436 Ref: Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. PMID: 19858398 |
Ref: CpG island methylation of BNIP3 predicts resistance against S-1/CPT-11 combined therapy in colorectal cancer patients. PMID: 19956881 Ref: Alternative-splicing forms of the major phase II conjugating UGT1A gene negatively regulate glucuronidation in human carcinoma cell lines. PMID: 19997083 Ref: Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism. PMID: 20028383 Ref: [Prerequisites to the administration and prevention of adverse effects of chemotherapy in colorectal cancer]. PMID: 20080456 Ref: Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cells. PMID: 20096102 Ref: Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation. PMID: 20196838 Ref: UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. PMID: 20628391 Ref: [Recent developments of pharmacogenomics in the treatment of colorectal cancers]. PMID: 20637356 Ref: Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom. PMID: 20661248 Ref: Cost-effectiveness of UGT1A1*28 genotyping in preventing severe neutropenia following FOLFIRI therapy in colorectal cancer. PMID: 21486535 |
Ref: Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. PMID: 20177420 Ref: Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: a prospective study. PMID: 20647221 Ref: Effects of methimazole on the elimination of irinotecan. PMID: 20680278 Ref: UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer. PMID: 20957480 Ref: Phase I/II study of FOLFIRI in Japanese patients with advanced colorectal cancer. PMID: 20965940 Ref: Immunohistochemical expression of conjugating UGT1A-derived isoforms in normal and tumoral drug-metabolizing tissues in humans. PMID: 21171088 Ref: Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients. PMID: 21287524 Ref: Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer. PMID: 21310730 Ref: Role of genetic polymorphisms and mutations in colorectal cancer therapy (Review). PMID: 21468552 Ref: Concurrence of UGT1A polymorphism and end-stage renal disease leads to severe toxicities of irinotecan in a patient with metastatic colon cancer. PMID: 21617725 Ref: A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. PMID: 21654688 Ref: A combined experimental and mathematical approach for molecular-based optimization of irinotecan circadian delivery. PMID: 21931543 Ref: Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer. PMID: 22045187 |
Ref: Review of biomarkers in colorectal cancer. PMID: 21040359 Ref: Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. PMID: 21893437 Ref: Association of serum bilirubin and promoter variations in HMOX1 and UGT1A1 genes with sporadic colorectal cancer. PMID: 22212955 Ref: Ugt1a is required for the protective effect of selenium against irinotecan-induced toxicity. PMID: 22237959 Ref: A phase I study of infusional 5-fluorouracil, leucovorin, oxaliplatin and irinotecan in Japanese patients with advanced colorectal cancer who harbor UGT1A1*1/*1,*1/*6 or *1/*28. PMID: 22508373 Ref: Meat-related mutagen exposure, xenobiotic metabolizing gene polymorphisms and the risk of advanced colorectal adenoma and cancer. PMID: 22552404 Ref: Effects of phytochemicals sulforaphane on uridine diphosphate-glucuronosyltransferase expression as well as cell-cycle arrest and apoptosis in human colon cancer Caco-2 cells. PMID: 22559738 Ref: Promoter length polymorphism in UGT1A1 and the risk of sporadic colorectal cancer. PMID: 22559977 Ref: ERCC1 C118T associates with response to FOLFOX4 chemotherapy in colorectal cancer patients in Han Chinese. PMID: 22567180 Ref: Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53. PMID: 22610353 Ref: Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies. PMID: 22674635 Ref: Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene. PMID: 22740978 Ref: Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients. PMID: 22909207 Ref: [The UGT1A, Nrf2 and Keap1 protein expression and significance in colon tumor]. PMID: 22943825 Ref: Splice isoforms as therapeutic targets for colorectal cancer. PMID: 23118106 Ref: Patterns of cancer genetic testing: a randomized survey of Oregon clinicians. PMID: 23150730 Ref: UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil. PMID: 23236239 Ref: [Genetic and epigenetic changes in colorectal cancer and genetic testing for personalized medicine]. PMID: 23323463 Ref: Predictors of irinotecan toxicity and efficacy in treatment of metastatic colorectal cancer. PMID: 23631285 |
Ref: Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy. PMID: 23303296 Ref: Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens. PMID: 23386248 Ref: Polymorphic expression of UDP-glucuronosyltransferase UGTlA gene in human colorectal cancer. PMID: 23468910 Ref: Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians. PMID: 23516488 Ref: Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer. PMID: 23543295 Ref: Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis. PMID: 23597015 Ref: [Effects of autophagy modulator on autophagy and uridine 5'-diphospho-glucuronosyltransferase 1A1 induced by sulforaphane]. PMID: 23663345 Ref: UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients. PMID: 23686699 Ref: Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai. PMID: 23892411 Ref: The role of tumor markers and biomarkers in colorectal cancer. PMID: 24050544 Ref: UDP-glucuronosyltransferase 1A compromises intracellular accumulation and anti-cancer effect of tanshinone IIA in human colon cancer cells. PMID: 24244442 |
Ref: Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation. PMID: 23493335 Ref: Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians. PMID: 23529007 Ref: Usefulness of one-point plasma SN-38G/SN-38 concentration ratios as a substitute for UGT1A1 genetic information after irinotecan administration. PMID: 23605141 Ref: The role of tumor markers and biomarkers in colorectal cancer. PMID: 24195503 Ref: Relationship between the expression of CES2, UGT1A1, and GUSB in colorectal cancer tissues and aberrant methylation. PMID: 24195516 Ref: Pretreatment selection of regimen according to genetic analysis improves the efficacy of chemotherapy in the first line treatment of metastatic colorectal cancer. PMID: 24318863 Ref: Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms. PMID: 24382596 Ref: Prospective phase II trial of second-line FOLFIRI in patients with advanced colorectal cancer including analysis of UGT1A1 polymorphisms: FLIGHT 2 study. PMID: 24403462 Ref: Regulation and expression of aberrant methylation on irinotecan metabolic genes CES2, UGT1A1 and GUSB in the in-vitro cultured colorectal cancer cells. PMID: 24439671 Ref: Modulatory effect of troxerutin on biotransforming enzymes and preneoplasic lesions induced by 1,2-dimethylhydrazine in rat colon carcinogenesis. PMID: 24512697 Ref: Glucosinolates from pak choi and broccoli induce enzymes and inhibit inflammation and colon cancer differently. PMID: 24714741 Ref: FOLFIRI(R) and bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms. PMID: 24758527 Ref: The effect of UGT1A and UGT2B polymorphisms on colorectal cancer risk: haplotype associations and gene-environment interactions. PMID: 24822274 Ref: [Interest of UGT1A1 genotyping within digestive cancers treatment by irinotecan]. PMID: 24977443 Ref: UGT1A1*28 polymorphisms: a potential pharmacological biomarker of irinotecan-based chemotherapies in colorectal cancer. PMID: 25141892 Ref: The power of genes: a case of unusually severe systemic toxicity after localized hepatic chemoembolization with irinotecan-eluted microspheres for metastatic colon cancer. PMID: 25202035 Ref: UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib. PMID: 25210794 Ref: Influence of UGT1A1 gene methylation level in colorectal cancer cells on the sensitivity of the chemotherapy drug CPT-11. PMID: 25260839 Ref: Effects of co-treatment with sulforaphane and autophagy modulators on uridine 5'-diphospho-glucuronosyltransferase 1A isoforms and cytochrome P450 3A4 expression in Caco-2 human colon cancer cells. PMID: 25364403 Ref: FOLFIRI and regorafenib combination therapy with dose escalation of irinotecan as fourth-line treatment for patients with metastatic colon cancer according to UGT1A1 genotyping. PMID: 25473295 Ref: Cost-Effectiveness Analysis of Ugt1a1 Genotyping Before Colorectal Cancer Treatment with Irinotecan. PMID: 27202308 |
Ref: Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the simultaneous determination of irinotecan and its main metabolites in human plasma and its application in a clinical pharmacokinetic study. PMID: 25689738 Ref: UDP-glucuronosyltransferase 1A determinates intracellular accumulation and anti-cancer effect of beta-lapachone in human colon cancer cells. PMID: 25692465 Ref: DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. PMID: 25782327 Ref: Costs and effectiveness of genomic testing in the management of colorectal cancer. PMID: 25783977 Ref: Personalized treatment for patients with colorectal cancer: role of biomarkers. PMID: 25808438 Ref: UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice. PMID: 25817555 Ref: An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients. PMID: 25880011 Ref: [Examination of UGT1A1 polymorphisms and irinotecan-induced neutropenia in patients with Colorectal cancer]. PMID: 25981652 Ref: [The role of assessing UGT1A1 gene polymorphism in the prediction of irinotecan-induced toxicity in the course of chemotherapy for colorectal cancer]. PMID: 26087609 Ref: [Companion Diagnostics Sub-Section of Anatomic Pathology Department in a Mid-Sized General Hospital: Start Up and Maintenance]. PMID: 26591440 |
Ref: Development of Pyrosequencing Method for Detection of UGT1A1 Polymorphisms in Thai Colorectal Cancers. PMID: 25545261 Ref: The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance. PMID: 26098842 Ref: Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer. PMID: 26632033 Ref: UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer. PMID: 26710796 Ref: Reduction of p53 by knockdown of the UGT1 locus in colon epithelial cells causes an increase in tumorigenesis. PMID: 26807433 Ref: Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial. PMID: 26811156 Ref: Molecular Genetics External Quality Assessment Pilot Scheme for Irinotecan-Related UGT1A1 Genotyping in China. PMID: 26820647 Ref: Correlation of UGT1A1(*)28 and (*)6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients. PMID: 26830078 Ref: Clinicopathological observation of primary lung enteric adenocarcinoma and its response to chemotherapy: A case report and review of the literature. PMID: 26889240 Ref: Molecular testing to optimize therapeutic decision making in advanced colorectal cancer. PMID: 27034809 Ref: Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients. PMID: 27116457 Ref: Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy. PMID: 27122675 Ref: UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer. PMID: 27220761 Ref: Erratum to: UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer. PMID: 27380166 Ref: DPYD*2A/*5A/*9A and UGT1A1*6/*28 polymorphisms in Chinese colorectal cancer patients. PMID: 27461651 Ref: [A Case of Unresectable Advanced Rectal Cancer with a Pancreatic Tumor That Was Successfully Treated with FOLFIRINOX]. PMID: 28133357 |
Ref: Cross-Talk between Alternatively Spliced UGT1A Isoforms and Colon Cancer Cell Metabolism. PMID: 28049773 Ref: Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer. PMID: 28209749 Ref: Relationship between UGT1A1*6/*28 gene polymorphisms and the efficacy and toxicity of irinotecan-based chemotherapy. PMID: 28790841 Ref: UGT1A1 Gene Polymorphism Predicts Irinotecan-Induced Severe Neutropenia and Diarrhea in Chinese Cancer Patients. PMID: 28879724 Ref: Prediction of Response to Irinotecan and Drug Toxicity Based on Pharmacogenomics Test: A Prospective Case Study in Advanced Colorectal Cancer PMID: 29072417 Ref: Association of insertion-deletions polymorphisms with colorectal cancer risk and clinical features. PMID: 29085228 Ref: Genotype-driven phase I study of weekly irinotecan in combination with capecitabine-based neoadjuvant chemoradiation for locally advanced rectal cancer. PMID: 29273261 Ref: Analysis of 12 variants in the development of gastric and colorectal cancers. PMID: 29358861 |
Ref: Structure-Dependent Modulation of Aryl Hydrocarbon Receptor-Mediated Activities by Flavonoids. PMID: 29584932 Ref: Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview. PMID: 29589315 Ref: Modulation of UDP-glucuronidation by acridinone antitumor agents C-1305 and C-1311 in HepG2 and HT29 cell lines, despite slight impact in noncellular systems. PMID: 29649683 Ref: UGT1A polymorphisms associated with worse outcome in colorectal cancer patients treated with irinotecan-based chemotherapy. PMID: 29728798 Ref: Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial. PMID: 29909091 Ref: Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation. PMID: 30075835 Ref: Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan. PMID: 30213564 Ref: UGT1A1 polymorphisms in rectal cancer associated with the efficacy and toxicity of preoperative chemoradiotherapy using irinotecan. PMID: 30246377 Ref: A phase II study of NK012, a polymeric micelle formulation of SN-38, in unresectable, metastatic or recurrent colorectal cancer patients. PMID: 30284603 Ref: The genotype for DPYD risk variants in colorectal cancer patients and the related toxicity management costs in clinical practice. PMID: 30339275 Ref: Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer. PMID: 30377777 |